| Not Yet Recruiting | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab NCT04266730 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab i NCT07009925 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cel NCT07444281 | Shanghai AbelZeta Ltd. | Phase 1 |
| Active Not Recruiting | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Adva NCT06403436 | TOLREMO therapeutics AG | Phase 1 |
| Completed | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Expr NCT05292859 | Alaunos Therapeutics | — |
| Withdrawn | CISH Inactivated TILs in the Treatment of NSCLC NCT05566223 | Intima Bioscience, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of ZEN003694 in People With Squamous Cell Lung Cancer NCT05607108 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innov NCT05550961 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Terminated | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors NCT05194735 | Alaunos Therapeutics | Phase 1 / Phase 2 |
| Enrolling By Invitation | The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma NCT06647836 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Completed | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locati NCT04357873 | UNICANCER | Phase 2 |
| Recruiting | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients NCT04566432 | Geneplus-Beijing Co. Ltd. | — |
| Completed | Prevalence of EGFR Mutations in epidermoïd Bronchopulmonary Cancers in Réunion Island NCT04261725 | Centre Hospitalier Universitaire de la Réunion | — |
| Unknown | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) NCT04025424 | Russian Academy of Medical Sciences | — |
| Terminated | FGFR Inhibitor in FGFR Dysregulated Cancer NCT03827850 | Lung Cancer Group Cologne | Phase 2 |
| Completed | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer NCT03866993 | Akeso | Phase 3 |
| Withdrawn | Photodynamic Therapy for the Prevention of Lung Cancer NCT03346304 | University College, London | Phase 2 / Phase 3 |
| Terminated | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 NCT03574818 | Montefiore Medical Center | Phase 2 |
| Unknown | Exhaled Breath Particles in Lung Cancer NCT05395611 | Lund University Hospital | — |
| Completed | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC NCT03177291 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Plati NCT03823625 | Fondazione Ricerca Traslazionale | Phase 2 |
| Recruiting | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression NCT03198546 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Completed | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China NCT03059641 | Geneplus-Beijing Co. Ltd. | — |
| Terminated | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary NCT03041181 | Nasser Hanna, M.D. | Phase 2 |
| Unknown | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in NCT02787473 | First People's Hospital of Hangzhou | Phase 2 |
| Unknown | A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCL NCT02852083 | University Hospital Regensburg | Phase 2 |
| Unknown | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers NCT02583542 | Queen Mary University of London | Phase 1 / Phase 2 |
| Completed | Icotinib for Completed Resected IB NSCLC With EGFR Mutation NCT02264210 | Sun Yat-sen University | Phase 2 |
| Unknown | Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer NCT02288026 | Capital Medical University | — |
| Completed | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell NCT01958372 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Unknown | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers NCT02423590 | Queen Mary University of London | Phase 2 |
| Withdrawn | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC NCT02059967 | Virginia Commonwealth University | Phase 1 |
| Completed | Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small NCT01784640 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Ch NCT01948141 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cance NCT01824901 | ECOG-ACRIN Cancer Research Group | Phase 1 / Phase 2 |
| Completed | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorect NCT01726296 | Fox Chase Cancer Center | N/A |
| Unknown | Autologous Natural Killer T Cells Infusion for the Treatment of Cancer NCT01801852 | Chinese PLA General Hospital | N/A |
| Unknown | Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemot NCT01660399 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Terminated | Dasatinib in Advanced Squamous Cell Lung Cancer NCT01491633 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer NCT01383668 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination NCT01345851 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Pre NCT01082549 | Sanofi | Phase 3 |
| Suspended | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer NCT00909558 | Envita Medical Center, Inc. | Phase 1 |
| Completed | Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease NCT01396603 | Massachusetts General Hospital | — |
| Withdrawn | Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease NCT00784329 | Lahey Clinic | N/A |
| Completed | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage NCT01557959 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB NCT00387374 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell L NCT00368992 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Sta NCT00118183 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer NCT00087412 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Photodynamic Therapy in Treating Patients With Lung Cancer NCT01668823 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Remov NCT00049543 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III N NCT00042835 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell NCT00040794 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III N NCT00020709 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non NCT00005838 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer NCT00002852 | National Cancer Institute (NCI) | Phase 3 |